Insulin detemir causes lesser weight gain in comparison to insulin glargine: Role on hypothalamic NPY and galanin

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Zafar, Mohammad Ishraq ^a   Hu, Cuining ^a   Liu, Danfeng ^a   Shafqat, Raja Adeel ^a   Gao, Feng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GALANIN; GLUCOSE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; MESSENGER RNA; NEUROPEPTIDE Y; ANTIDIABETIC AGENT; GAL PROTEIN, RAT; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN; PROTEIN PRECURSOR; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES CONTROL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPOTHALAMUS; INSULIN TREATMENT; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RAT; WEIGHT CHANGE; WEIGHT GAIN; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EATING; FEEDING BEHAVIOR; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; EATING; FEEDING BEHAVIOR; GALANIN; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; INSULIN, LONG-ACTING; NEUROPEPTIDE Y; PROTEIN PRECURSORS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STREPTOZOCIN; WEIGHT GAIN;

EID: 84907420846     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/458104     Document Type: Article

References (27)

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030," Diabetes Care, vol. 27,no. 5, pp. 1047-1053, 2004.
2. Y. Xu, L. Wang, J. He et al., "Prevalence and control of diabetes in Chinese adults," Journal of the American Medical Association, vol. 310, no. 9, pp. 948-958, 2013.
3. J. Q. Purnell, B. Zinman, J. D. Brunzell, P. A. Cleary, D. M. Nathan, and J. M. Lachin, "The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study," Circulation, vol. 127, no. 2, pp. 180-187, 2013.
4. M. A. Banerji, M. A. Baron, L. Gao, and L. Blonde, "Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents," Postgraduate Medicine, vol. 126, no. 3, pp. 111-125, 2014.
5. U. Pedersen-Bjergaard, P. L. Kristensen, and H. Beck-Nielsen, "Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, openlabel, blinded-endpoint crossover trial," The Lancet Diabetes & Endocrinology, vol. 2, no. 7, pp. 553-561, 2014.
6. G. Koehler, G. Treiber, A. Wutte et al., "Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single doses and under steady-state conditions in patients with type 1 diabetes," Diabetes, Obesity and Metabolism, vol. 16, no. 1, pp. 57-62, 2014.
7. M. Hod, E. R. Mathiesen, L. Jovanovič et al., "A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes," Journal of Maternal-Fetal and Neonatal Medicine, vol. 27, no. 1, pp. 7-13, 2014.
8. J. G. Smith, T. A. Manuck, J. White, and D. C. Merrill, "Insulin glargine versus neutral protamine hagedorn insulin for treatment of diabetes in pregnancy," American Journal of Perinatology, vol. 26, no. 1, pp. 57-62, 2009.
9. J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, "A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes," Diabetologia, vol. 51, no. 3, pp. 408-416, 2008.
10. R. S. Egerman, R. D. Ramsey, L. W. Kao et al., "Perinatal outcomes in pregnancies managed with antenatal insulin glargine," The American Journal of Perinatology, vol. 26,no. 8, pp. 591-595, 2009.
11. S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. Devries, "Insulin detemir versus insulin glargine for type 2 diabetes mellitus.," Cochrane Database of Systematic Reviews, no. 7, 2011.
12. O. Klein, J. Lynge, L. Endahl, B. Damholt, L. Nosek, and T. Heise, "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes," Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 290-299, 2007.
13. M. Hallschmid, K. Jauch-Chara, O. Korn et al., "Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects," Diabetes, vol. 59, no. 4, pp. 1101-1107, 2010.
14. A. Sahu, "Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat," Endocrinology, vol. 139, no. 11,pp. 4739-4742, 1998.
15. K. Tatemoto and Y. Neuropeptide, History and Overview, Handbook of Experimental Pharmacology, vol. 162, Springer, Berlin, Germany, 2004.
16. P. Fang, M. Yu, L. Guo, P. Bo, Z. Zhang, and M. Shi, "Galanin and its receptors: a novel strategy for appetite control and obesity therapy," Peptides, vol. 36, no. 2, pp. 331-339, 2012.
17. A. O. Schaffhauser, A. Stricker-Krongrad, L. Brunner et al., "Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides," Diabetes, vol. 46, no. 11, pp. 1792-1798, 1997.
18. M. S. Winzell and B. Ahrén, "The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes," Diabetes, vol. 53, supplement 3, pp. S215-S219, 2004.
19. K. Srinivasan, B.Viswanad, L.Asrat, C. L. Kaul, and P. Ramarao, "Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening," Pharmacological Research, vol. 52,no. 4, pp. 313-320, 2005.
20. P.Hollander, J. Cooper, J. Bregnhøj, and C. B. Pedersen, "A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes," Clinical Therapeutics, vol. 30, no. 11, pp. 1976-1987, 2008.
21. C. Sobrino Crespo, A. Perianes Cachero, L. Puebla Jiménez, V. Barrios, and E. Arilla Ferreiro, "Peptides and food intake," Frontiers in Endocrinology, vol. 5, article 58, 2014.
22. D. K. Sindelar, P. Mystkowski, D. J. Marsh, R. D. Palmiter, and M. W. Schwartz, "Attenuation of diabetic hyperphagia in neuropeptide Y-deficient mice," Diabetes, vol. 51, no. 3, pp. 778-783, 2002.
23. K.Mitsukawa, X. Lu, and T. Bartfai, "Galanin, galanin receptors, and drug targets.," EXS, vol. 102, pp. 7-23, 2010.
24. J.Wang and K. L. Leibowitz, "Central insulin inhibits hypothalamic galanin and neuropeptide Y gene expression and peptide release in intact rats," Brain Research, vol. 777, no. 1-2, pp. 231-236, 1997.
25. P. A. Hollander, "Insulin detemir for the treatment of obese patients with type 2 diabetes," Diabetes, Metabolic Syndrome and Obesity, vol. 5, pp. 11-19, 2012.
26. A. M. Hennige, T. Sartorius, O. Tschritter et al., "Tissue selectivity of insulin detemir action in vivo," Diabetologia, vol. 49, no. 6, pp. 1274-1282, 2006.
27. S.N. Singh, P. Vats, R. Shyam et al., "Role of neuropeptide Y and galanin in high altitude induced anorexia in rats," Nutritional Neuroscience, vol. 4, no. 4, pp. 323-331, 2001.